Semaglutide 2.4 mg for weight regain after bariatric surgery in adults with obesity
Tests semaglutide 2.4 mg against placebo in adults with obesity after bariatric surgery.
Key facts
- Who runs it
- Stichting Zuyderland Medisch Centrum
- Where
- Beverwijk, Heerlen, and Nieuwegein, NetherlandsSee the 3 sites
- Trial code
- EU 2022-502164-20-01
- U1111-1273-2041
- Registry title
- Semaglutide 2.4mg for low responders after bariatric surgery
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 152 people, planned
- Started
- 11 Mar 2025
- Planned end
- 30 Jan 2026
- Type of study
- Interventional
- Record updated
- 6 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had weight-loss surgery (gastric bypass or sleeve gastrectomy) and lost the least weight in the first 3 months. They would get Semaglutide 2.4 mg or placebo, plus a lifestyle programme.
- Age
- 18 years or older, and younger than 75 years
- Sex
- All sexes can join.
- Disease stage
- Obesity with a BMI of 35.0 kg/m2 or more before surgery. After surgery, the person is in the lowest quarter for weight loss (%TWL) at 3 months.
- Earlier treatment
- Must have had a first gastric bypass (RYGB, banded or not) or a sleeve gastrectomy (SG, banded or not). Must be treated with group consultation at the Dutch Obesity Clinic (DOC).
Main reasons for not taking part
- Type 1 or type 2 diabetes
- Use of warfarin or other coumarin drugs
- Poor kidney function (creatinine clearance below 30 ml/min) or any liver failure
- Serious heart failure or angina (NYHA class III and IV)
- Past cancer, past pancreatitis, or past thyroid cancer
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patient is ≥18 and <75 years old
- BMI before surgery was ≥ 35.0 kg/m2
- Patient is treated with group consultation at the Dutch Obesity Clinic (DOC)
- Patient has undergone a primary (banded) RYGB or (banded) sleeve gastrectomy (SG)
- Patient is in the lowest %TWL quartile, 3 months after surgery and will be enrolled in the plus module
Who cannot take part
- Type 1 or type 2 diabetes
- Liver failure (all)
- Congestive heart failure or angina pectoris NYHA class III and IV
- Malignancy in history
- Inflammatory Bowel Disease
- Thyroid malignancy in history
- Decreased renal function (creatinine clearance < 30 ml/min)
- Use of warfarin or other coumarin derivates
- Pancreatitis (in history)
- Pregnancy / breast-feeding
Where in Netherlands
- Rode Kruis Ziekenhuis B.V.Beverwijk, NetherlandsTaking people
- Zuyderland Medisch Centrum StichtingHeerlen, NetherlandsTaking people
- Sint Antonius Ziekenhuis StichtingNieuwegein, NetherlandsTaking people
About the trial
What the trial wants to find out
To study the weight change from 3 to 18 months after surgery (% total weight loss, TWL) in low responders after bariatric surgery who are treated with Semaglutide 2.4 mg and a lifestyle intervention and compare change in weight to patients receiving placebo and a lifestyle intervention.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Semaglutide 2.4mg for low responders after bariatric surgery
- Plain-language title
- Semaglutide 2.4 mg for weight regain after bariatric surgery in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 6 March 2025